JP4131568B2 - 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用 - Google Patents

代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用 Download PDF

Info

Publication number
JP4131568B2
JP4131568B2 JP50011898A JP50011898A JP4131568B2 JP 4131568 B2 JP4131568 B2 JP 4131568B2 JP 50011898 A JP50011898 A JP 50011898A JP 50011898 A JP50011898 A JP 50011898A JP 4131568 B2 JP4131568 B2 JP 4131568B2
Authority
JP
Japan
Prior art keywords
gaba
receptor
protein
cgp
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50011898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515005A (ja
JP2000515005A5 (enExample
Inventor
カウプマン，クレメンス
ベットラー，ベルンハルト
ビッティガー，ヘルムート
フレストル，ボルフガング
ミッケル，スチュアート・ジョン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2000515005A publication Critical patent/JP2000515005A/ja
Publication of JP2000515005A5 publication Critical patent/JP2000515005A5/ja
Application granted granted Critical
Publication of JP4131568B2 publication Critical patent/JP4131568B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50011898A 1996-05-30 1997-03-19 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用 Expired - Fee Related JP4131568B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65571696A 1996-05-30 1996-05-30
US08/655,716 1996-05-30
US75609196A 1996-11-22 1996-11-22
US08/756,091 1996-11-22
PCT/EP1997/001370 WO1997046675A1 (en) 1996-05-30 1997-03-19 Metabotropic gaba[b] receptors, receptor-specific ligands and their uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007108678A Division JP2007289188A (ja) 1996-05-30 2007-04-17 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用
JP2007291036A Division JP4202403B2 (ja) 1996-05-30 2007-11-08 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用

Publications (3)

Publication Number Publication Date
JP2000515005A JP2000515005A (ja) 2000-11-14
JP2000515005A5 JP2000515005A5 (enExample) 2004-12-02
JP4131568B2 true JP4131568B2 (ja) 2008-08-13

Family

ID=27097014

Family Applications (3)

Application Number Title Priority Date Filing Date
JP50011898A Expired - Fee Related JP4131568B2 (ja) 1996-05-30 1997-03-19 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用
JP2007108678A Pending JP2007289188A (ja) 1996-05-30 2007-04-17 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用
JP2007291036A Expired - Fee Related JP4202403B2 (ja) 1996-05-30 2007-11-08 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007108678A Pending JP2007289188A (ja) 1996-05-30 2007-04-17 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用
JP2007291036A Expired - Fee Related JP4202403B2 (ja) 1996-05-30 2007-11-08 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用

Country Status (9)

Country Link
EP (1) EP0907731B1 (enExample)
JP (3) JP4131568B2 (enExample)
AT (1) ATE290079T1 (enExample)
AU (1) AU2028497A (enExample)
CA (1) CA2254862A1 (enExample)
DE (1) DE69732631T2 (enExample)
ES (1) ES2239352T3 (enExample)
PT (1) PT907731E (enExample)
WO (1) WO1997046675A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2308102A1 (en) * 1997-10-27 1999-05-06 Astrazeneca Aktiebolag New nucleotide sequences
JP2002502859A (ja) * 1998-02-05 2002-01-29 メルク エンド カムパニー インコーポレーテッド 新規ｇａｂａｂ受容体ｄｎａ配列
EP0937777A3 (en) * 1998-02-20 1999-11-24 Smithkline Beecham Plc GABA receptors and their uses
EP1066325A1 (en) * 1998-04-03 2001-01-10 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gaba b? receptors
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
WO1999051636A2 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Gaba b receptor
WO1999058567A1 (en) * 1998-05-08 1999-11-18 Smithkline Beecham Corporation GABAB1b RECEPTOR
AUPP438498A0 (en) * 1998-06-29 1998-07-23 Garvan Institute Of Medical Research Novel Gaba-B receptor
JP2002523070A (ja) * 1998-09-01 2002-07-30 スミスクライン ビーチャム コーポレーション Ｇａｂａｂ１ａａ受容体
WO2000014222A2 (en) * 1998-09-07 2000-03-16 Glaxo Group Limited GABAB RECEPTOR SUBTYPES GABAB-R1c AND GABAB-R2 AND HETERODIMERS THEREOF
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
GB9906882D0 (en) * 1999-03-25 1999-05-19 Novartis Ag Organic compounds
SE9901659D0 (sv) 1999-05-06 1999-05-06 Astra Ab New methods
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
US6787646B1 (en) * 1999-11-12 2004-09-07 Immusol, Inc. Tumor suppressor molecules and methods of use
DE19955408A1 (de) * 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
WO2004083855A1 (en) * 2003-03-19 2004-09-30 Solvo Biotechnology, Inc. Method for the identification of cells specifically modulating slow inhibition in the neocortex
CN102532197A (zh) * 2010-12-24 2012-07-04 中国科学院上海药物研究所 一类光亲和标记双功能探针分子及其制备方法和应用
CN108588087B (zh) * 2018-05-16 2022-06-03 南京农业大学 一种提高植物抗病性的基因GmLecRK-R及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids

Also Published As

Publication number Publication date
CA2254862A1 (en) 1997-12-11
DE69732631D1 (de) 2005-04-07
EP0907731B1 (en) 2005-03-02
ATE290079T1 (de) 2005-03-15
JP2000515005A (ja) 2000-11-14
AU2028497A (en) 1998-01-05
JP4202403B2 (ja) 2008-12-24
JP2008113662A (ja) 2008-05-22
JP2007289188A (ja) 2007-11-08
PT907731E (pt) 2005-07-29
DE69732631T2 (de) 2005-12-29
WO1997046675A1 (en) 1997-12-11
ES2239352T3 (es) 2005-09-16
EP0907731A1 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
JP4202403B2 (ja) 代謝調節型ｇａｂａ［ｂ］レセプター、レセプター特異的リガンドおよびそれらの使用
RU2146132C1 (ru) Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция
US6379925B1 (en) Angiogenic modulation by notch signal transduction
JP2000516467A (ja) 哺乳動物細胞表面抗原；関連試薬
US6368824B1 (en) Neuropeptide Y receptor Y5 and nucleic acid sequences
US7115394B2 (en) Hedgehog interacting proteins and uses related thereto
US20040110706A1 (en) Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
JP4833467B2 (ja) 新規カリウムチャネル及び同カリウムチャネルをコードする遺伝子
JP2005500803A (ja) 破骨細胞関連レセプター
US7119189B2 (en) Metabotropic GABA [B] receptors, receptor-specific ligands and their uses
US8038995B2 (en) Human N-type calcium channel isoform and uses thereof
WO1999001468A2 (en) Vertebrate smoothened gene, gene products, and uses related thereto
US6649371B1 (en) Potassium channel KCNQ5 and sequences encoding the same
US20030092035A1 (en) Pain signaling molecules
US20030119726A1 (en) P-glycoproteins and uses thereof
EP1037982A1 (en) Human patched genes and proteins, and uses related thereto
JP4257322B2 (ja) カルシウム受容体をコードする核酸分子
JPH10117791A (ja) ヒトｇタンパク質結合受容体ｈｌｙａｚ６１
JP2005505275A (ja) ヒトカリウムチャネルファミリーメンバーの３３７５１を使用する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080520

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080527

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110606

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110606

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120606

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees